FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2102598497> ?p ?o ?g. }

• W2102598497 endingPage "374" @default.
• W2102598497 startingPage "366" @default.
• W2102598497 abstract "Abstract BACKGROUND Small cell lung carcinoma (SCLC) cell lines commonly express KIT and its ligand, stem cell factor, suggesting an autocrine loop promoting cell growth. Imatinib inhibits KIT kinase activity. SCLC cells treated with imatinib in vitro undergo cell cycle arrest. Imatinib reduces resistance to irinotecan in vitro. Common metabolic pathways suggest there may be drug interactions between imatinib and irinotecan or cisplatin. In the current study, the authors investigated the feasibility of combining these drugs in the treatment of patients with SCLC. METHODS Two Phase I studies were conducted independently at two institutions. Patients with extensive‐disease SCLC underwent therapy with cisplatin, irinotecan, and imatinib using two similar regimens. In one study, immunohistochemical analysis of the expression of potential imatinib targets was performed on pretreatment biopsy specimens, and blood specimens were collected and analyzed for imatinib, irinotecan, and cisplatin pharmacokinetic parameters. RESULTS Nine patients were enrolled and were evaluable for toxicity. A high incidence of neutropenia, diarrhea, and thrombosis was observed that precluded dose escalation. Six patients were evaluable for response after four cycles; five patients experienced a partial response and the other patient had developed progressive disease. Four of six tumor specimens tested expressed platelet‐derived growth factor receptor‐α and two expressed KIT. Irinotecan clearance was found to be significantly decreased by imatinib ( P < 0.04). No significant alteration in the disposition of cisplatin was observed. CONCLUSIONS The maximum tolerated dose for this combination with granulocyte–colony‐stimulating factor support was identified as imatinib at a dose of 300 mg/day with irinotecan (at a dose of 65 mg/m 2 ) and cisplatin (at a dose of 30 mg/m 2 ) given on Days 1 and 8, every 21 days. The decreased irinotecan clearance may explain the high incidence of diarrhea and neutropenia noted in the current study. Cancer 2006. © 2005 American Cancer Society." @default.
• W2102598497 created "2016-06-24" @default.
• W2102598497 creator A5018095635 @default.
• W2102598497 creator A5024203346 @default.
• W2102598497 creator A5033948459 @default.
• W2102598497 creator A5050489521 @default.
• W2102598497 creator A5056267838 @default.
• W2102598497 creator A5073466449 @default.
• W2102598497 creator A5081694935 @default.
• W2102598497 creator A5087156478 @default.
• W2102598497 creator A5089628178 @default.
• W2102598497 date "2005-12-09" @default.
• W2102598497 modified "2023-10-12" @default.
• W2102598497 title "Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma" @default.
• W2102598497 cites W1570233631 @default.
• W2102598497 cites W1965624945 @default.
• W2102598497 cites W1973145002 @default.
• W2102598497 cites W1984246155 @default.
• W2102598497 cites W1985349868 @default.
• W2102598497 cites W1989305266 @default.
• W2102598497 cites W2000387410 @default.
• W2102598497 cites W2002374809 @default.
• W2102598497 cites W2002381578 @default.
• W2102598497 cites W2014566160 @default.
• W2102598497 cites W2015015957 @default.
• W2102598497 cites W2022216823 @default.
• W2102598497 cites W2034407706 @default.
• W2102598497 cites W2073683299 @default.
• W2102598497 cites W2078990365 @default.
• W2102598497 cites W2085352280 @default.
• W2102598497 cites W2095149773 @default.
• W2102598497 cites W2097457793 @default.
• W2102598497 cites W2112237195 @default.
• W2102598497 cites W2113231967 @default.
• W2102598497 cites W2139248078 @default.
• W2102598497 cites W2153701773 @default.
• W2102598497 cites W2154169171 @default.
• W2102598497 cites W2157332329 @default.
• W2102598497 cites W2167805334 @default.
• W2102598497 cites W2172761866 @default.
• W2102598497 cites W2174727426 @default.
• W2102598497 cites W2328017321 @default.
• W2102598497 cites W2329648702 @default.
• W2102598497 cites W2605234528 @default.
• W2102598497 cites W4321317624 @default.
• W2102598497 doi "https://doi.org/10.1002/cncr.21640" @default.
• W2102598497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16342249" @default.
• W2102598497 hasPublicationYear "2005" @default.
• W2102598497 type Work @default.
• W2102598497 sameAs 2102598497 @default.
• W2102598497 citedByCount "44" @default.
• W2102598497 countsByYear W21025984972012 @default.
• W2102598497 countsByYear W21025984972013 @default.
• W2102598497 countsByYear W21025984972014 @default.
• W2102598497 countsByYear W21025984972015 @default.
• W2102598497 countsByYear W21025984972018 @default.
• W2102598497 countsByYear W21025984972019 @default.
• W2102598497 countsByYear W21025984972022 @default.
• W2102598497 countsByYear W21025984972023 @default.
• W2102598497 crossrefType "journal-article" @default.
• W2102598497 hasAuthorship W2102598497A5018095635 @default.
• W2102598497 hasAuthorship W2102598497A5024203346 @default.
• W2102598497 hasAuthorship W2102598497A5033948459 @default.
• W2102598497 hasAuthorship W2102598497A5050489521 @default.
• W2102598497 hasAuthorship W2102598497A5056267838 @default.
• W2102598497 hasAuthorship W2102598497A5073466449 @default.
• W2102598497 hasAuthorship W2102598497A5081694935 @default.
• W2102598497 hasAuthorship W2102598497A5087156478 @default.
• W2102598497 hasAuthorship W2102598497A5089628178 @default.
• W2102598497 hasBestOaLocation W21025984971 @default.
• W2102598497 hasConcept C121608353 @default.
• W2102598497 hasConcept C126322002 @default.
• W2102598497 hasConcept C143998085 @default.
• W2102598497 hasConcept C2776694085 @default.
• W2102598497 hasConcept C2777583451 @default.
• W2102598497 hasConcept C2778239845 @default.
• W2102598497 hasConcept C2778729363 @default.
• W2102598497 hasConcept C2780259306 @default.
• W2102598497 hasConcept C3019892230 @default.
• W2102598497 hasConcept C526805850 @default.
• W2102598497 hasConcept C71924100 @default.
• W2102598497 hasConcept C90924648 @default.
• W2102598497 hasConcept C98274493 @default.
• W2102598497 hasConceptScore W2102598497C121608353 @default.
• W2102598497 hasConceptScore W2102598497C126322002 @default.
• W2102598497 hasConceptScore W2102598497C143998085 @default.
• W2102598497 hasConceptScore W2102598497C2776694085 @default.
• W2102598497 hasConceptScore W2102598497C2777583451 @default.
• W2102598497 hasConceptScore W2102598497C2778239845 @default.
• W2102598497 hasConceptScore W2102598497C2778729363 @default.
• W2102598497 hasConceptScore W2102598497C2780259306 @default.
• W2102598497 hasConceptScore W2102598497C3019892230 @default.
• W2102598497 hasConceptScore W2102598497C526805850 @default.
• W2102598497 hasConceptScore W2102598497C71924100 @default.
• W2102598497 hasConceptScore W2102598497C90924648 @default.
• W2102598497 hasConceptScore W2102598497C98274493 @default.
• W2102598497 hasIssue "2" @default.
• W2102598497 hasLocation W21025984971 @default.

• next